Navigation Links
Data Demonstrating the Safety and Efficacy of Chimerix's Antiviral CMX001 Presented at BMT Tandem Meetings
Date:2/19/2013

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001.  CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year.  

"These findings demonstrate CMX001's potential to be a safe and efficacious broad-spectrum antiviral for the treatment of double-stranded DNA viral infections," said M. Michelle Berrey , MD, MPH, Chief Medical Officer of Chimerix.  "As we progress CMX001 into a Phase 3 study for the prevention of cytomegalovirus infection in adults undergoing hematopoietic stem cell transplantation, these data support our desire to conduct additional clinical studies to evaluate the potential benefit of CMX001 against other double-stranded DNA viruses, including BK virus."

These data were presented during the Allogeneic Transplants Poster Session at the BMT Tandem Meetings in Salt Lake City on Saturday, February 16, 2013.

The three presentations included:

Renal Safety of the Broad-Spectrum Antiviral, CMX001, in the Prevention of Cytomegalovirus Infection Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Renal safety of CMX001 was assessed during Study 201, a Phase 2 study evaluating CMX001 for the prevention of CMV infection following allogeneic hematopoietic stem cell transplantation (HSCT).  A prospective analysis found that placebo recipients experienced a decline in renal function during the randomized treatment period, while there appeared to be a dose-related improvement in renal function for the CMX001-treated subjects.  The comparison between pooled placebo and the group receiving a CMX001 dose of 100 mg twice weekly reached statistical significance (p<0.05).  The lack of renal toxicity as well as the potential activity of CMX001 against BK virus are significant findings from this report.  CMX001 will be evaluated in the Phase 3 study, SUPPRESS, for prevention of CMV.  SUPPRESS will also explore the potential for activity against BK virus in HSCT.  

Monitoring Changes in Serum Albumin Concentrations as an Early and Objective Indicator of Potential CMX001-associated Gastrointestinal Adverse Drug Effects

In Study 201, diarrhea was found to be the dose-limiting side effect associated with CMX001.  As GI adverse events are common in this patient population, differentiating potential drug-related diarrhea from other etiologies is important to limit the impact of GI-related adverse events on optimal dosing duration in this population.  Decreases in serum albumin in association with worsening diarrhea can be used as a clinical and objective tool to discriminate drug-related diarrhea from diarrhea of other etiologies, prompting interruption of study drug in order to avoid progression to higher severity events.  Monitoring serum albumin levels has been incorporated into the overall Safety Monitoring and Management Plan for CMX001 and will be incorporated in the Phase 3 study, SUPPRESS.

BK virus-associated nephropathy (BKVN), an under-recognized cause of renal dysfunction in severely immunosuppressed hematopoietic stem cell transplant (HSCT) patients: Report of 5 cases of BKVN and the potential role of CMX001 for treatment

BK virus-associated nephropathy, BKVN, is observed in patients with renal transplants and is related to kidney graft loss.  In HSCT recipients, hemorrhagic cystitis (HC) is the most common BK virus manifestation.  A recent retrospective analysis at Memorial Sloan-Kettering Cancer Center revealed five cases of HSCT recipients with BKVN identified through biopsy or autopsy, and suggested that BKVN may be an under-recognized cause of renal dysfunction in HSCT recipients.  Through Chimerix's expanded access study of CMX001, a recipient of HSCT was treated for BKVN with CMX001 100 mg twice weekly for six months.  After 10 months of therapy, the patient has maintained stable renal function without requiring hemodialysis.  This case report suggests that BKVN may be underdiagnosed in HSCT recipients and should be considered in patients with declining renal function.  Furthermore, these data support the potential role of CMX001 for the treatment of BKV infection and BKVN.

About Chimerix and CMX001

Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need.  The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. 

Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients.  Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies.  Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections.  Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013. 

Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA). 

Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.   


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
2. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
3. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
4. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
5. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
6. Patient Safety, Science and Technology Summit Inspires Healthcare Industry Stakeholders to Action in Pursuit of 0 Preventable Patient Deaths by 2020
7. FDA Grants 510(k) clearance for new Fluke Biomedical ESA615 Electrical Safety Analyzer
8. Zebra Technologies Connects the Dots Between the Patient Experience and Safety
9. Seven Denver Area Hospitals Join Colorado Health Information Exchange To Support Advancements In Health Care Quality & Safety
10. Cognizant Recognized as a Leader in Life Science Drug Safety Services in IDC MarketScape
11. Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical Associates ... Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference ... providers an opportunity to learn about cutting edge treatments, to collaborate, share research ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before one’s passing is ... where to even begin. “Now more than ever there are some questions that are ... and your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl says ... work because the plan is given by the Creator Himself. , Yisrayl says war ...
(Date:4/21/2017)... Texas (PRWEB) , ... April 21, 2017 , ... ... sound familiar? These are five common elements between the Obamacare program that ... hog control program which uses Warfarin poison to kill hogs. , Like ...
Breaking Medicine News(10 mins):